REG - Destiny Pharma PLC - Director Shareholding Amendment

Destiny PharmaAnnouncement

18/11/2022 13:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221118:nRSR9500Ga&default-theme=true

RNS Number : 9500G  Destiny Pharma PLC  18 November 2022

 

Destiny Pharma plc

 

("Destiny Pharma" or the "Company")

 

Director Shareholding Amendment

 

Brighton, United Kingdom - 18 November 2022 - Destiny Pharma (AIM: DEST), a
clinical stage  biotechnology company focused on the development of novel
medicines to prevent  life threatening infections, announces that due to an
administrative oversight at the time of Nigel Brooksby's appointment to the
Board, as announced on 26 May 2022, his shareholding in Destiny Pharma was not
made known to the Company. The Company can now clarify that Mr. Brooksby holds
a beneficial interest in 348,750 ordinary shares in Destiny Pharma
representing 0.48 per cent. of the Company's issued share capital.

 

 

For further information, please contact:

 

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

+44 (0) 127 370 4440

pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

Optimum Strategic Communications

Mary Clark / Manel Mateus / Eleanor Cooper

+44 (0) 203 922 0891

DestinyPharma@optimumcomms.com (mailto:DestinyPharma@optimumcomms.com)

 

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

 

MC Services AG

Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

 

Stern IR - US

Janhavi Mohite

+1-212-362-1200

Janhavi.Mohite@sternir.com (mailto:Janhavi.Mohite@sternir.com)

 

 

About Destiny Pharma

 

Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development of novel medicines that can prevent life-threatening
infections. Its pipeline has novel microbiome-based biotherapeutics and XF
drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US and also XF-73 nasal gel, which
has recently completed a positive Phase 2b clinical trial targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA.
It is also co-developing SporCov, a novel, biotherapeutic product for the
prevention of COVID-19 and other viral respiratory infections and has earlier
grant funded XF research projects.

 

For further information on the company, please visit
https://www.destinypharma.com (https://www.destinypharma.com) .

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEADFPFFDAFFA